References
- Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. The Lancet Psychiatry. 2016;3(2):171–178.
- Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol. 2016;24(4):229.
- Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209–219.
- Dagher A. Retuning brain circuitry to treat mental illness: the role of functional neuroimaging. Commentary for the special issue: mechanisms of change. NeuroImage. 2017;151:128–129.
- Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008;75(1):17–33.
- Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.
- Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
- Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197.
- Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017;42:2114–2127.
- Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513.
- Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180.
- Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017;14(3):1–7.
- Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman RC, Willette RE, editors. The psychopharmacology of hallucinogens, 74–83. New York (NY): Pergamon Press; 1978.
- Wagner MT, Mithoefer MC, Mithoefer AT, et al. Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017;31(8):967–974.
- Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
- Suzuki K, Nosyreva E, Hunt KW, et al. Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 2017;546(7659):E1–E3.
- Abdallah CG, Averill LA, Collins KA, et al. Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology. 2017 May;42(6):1210–1219.